NCT07343401

Sarcoidosis Immunotsuppressive Therapy and Lymphoma Development

Impact of Immunosuppressive Therapy of Sarcoidosis on Lymphoma Development

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 40 (actual)
• Sponsor: Alexandria University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Impact of Immunosuppressive Therapy for Sarcoidosis on Lymphoma Development

Detailed description

This is a prospective observational cohort study to be conducted in the Chest Diseases Department, Alexandria Main University Hospital. A total of 40 adult patients (≥16 years) with biopsy-proven sarcoidosis will be consecutively recruited between December 2024 and December 2025. All patients will be either newly starting or continuing immunosuppressive therapy for sarcoidosis. The treatment regimen-systemic corticosteroids, conventional steroid-sparing agents (methotrexate, azathioprine, or mycophenolate), or biologics (anti-TNF agents)-will be recorded but not altered by study design. Each patient will be followed prospectively for 12 months from enrollment.

Conditions

• Sarcoidosis Lung

Interventions

Type	Name	Description
PROCEDURE	lymph node biopsy	sarcoidosis diagnosis by lymph node biopsy excisiona or bronchoscopic

Timeline

• Start date: 2025-08-01
• Primary completion: 2025-12-30
• Completion: 2026-01-01
• First posted: 2026-01-15
• Last updated: 2026-01-15

Locations

1 site across 1 country: Egypt